Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 8 (12), 1392-7

Efficacy of Killed Virus Vaccine, Live Attenuated Chimeric Virus Vaccine, and Passive Immunization for Prevention of West Nile Virus Encephalitis in Hamster Model

Affiliations

Efficacy of Killed Virus Vaccine, Live Attenuated Chimeric Virus Vaccine, and Passive Immunization for Prevention of West Nile Virus Encephalitis in Hamster Model

Robert B Tesh et al. Emerg Infect Dis.

Abstract

Results of experiments evaluating the efficacy of three immunization strategies for the prevention of West Nile virus (WNV) encephalitis are reported. Immunization strategies evaluated included a killed virus veterinary vaccine, a live attenuated chimeric virus vaccine candidate, and passive immunization with WNV-immune serum; all were tested by using a hamster model of the disease. Each product protected the animals from clinical illness and death when challenged with a hamster-virulent éwild-type WNV strain 1 month after initial immunization. The live attenuated chimeric virus vaccine candidate induced the highest humoral antibody responses, as measured by hemagglutination inhibition, complement fixation, and plaque reduction neutralization tests. Although the duration of protective immunity was not determined in this study, our preliminary results and the cumulative experience of other virus vaccines suggest that the live attenuated chimeric virus provides the longest lasting immunity.

Figures

Figure
Figure
Daily mean (plus or minus the standard deviation) virus titers and hemagglutination inhibition (HI) antibody levels in 10 naïve (control) hamsters after intraperitoneal inoculation of 104 TCID50 West Nile virus strain NY385-99.

Similar articles

See all similar articles

Cited by 45 PubMed Central articles

See all "Cited by" articles

References

    1. Monath TP Prospects for the development of a vaccine against the West Nile virus. Ann N Y Acad Sci. 2001;951:1–12 - PubMed
    1. Davis BS, Chang G-JJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol. 2001;75:4040–7 10.1128/JVI.75.9.4040-4047.2001 - DOI - PMC - PubMed
    1. Lustig S, Olshevsky U, Ben-Nathan D, Lachmi BE, Malkinson M, Kobiler D, et al. A live, attenuated West Nile virus strain as a potential veterinary vaccine. Viral Immunol. 2000;13:401–10 10.1089/vim.2000.13.401 - DOI - PubMed
    1. Pletnev AG, Putnak R, Speicher J, Wagar EJ, Vaughn DW West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci U S A. 2002;99:3036–41 10.1073/pnas.022652799 - DOI - PMC - PubMed
    1. Xiao S-Y, Guzman H, Zhang H Travassos da APA, Tesh, RB. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis. 2001;7:714–21 - PMC - PubMed

Publication types

LinkOut - more resources

Feedback